NTU designs molecular probe to track disease progression

However, for clinical trials in which disease progression time (TTP), progression-free survival (PFS) rate and other disease progression (PD) indicators are the main end points of the study, it is not emphasized that there must be measurable lesions, and only non-target lesions that cannot be measured can be included in the group.

Working with mice, the NTU scientists focused on two important disease indicators known as reactive nitrogen species (RNS) and reactive oxygen species (ROS) that have very similar chemical properties.

When there is inflammation, infection or cancer, or when a new drug is introduced in the body, RNS and ROS are among the first indicators to rise in their levels.

The respective levels of RNS and ROS change through the course of a disease, and are markedly different when the body is healthy, meaning that together they could be used to pinpoint disease stages.

However, while current imaging technologies can track RNS and ROS, they cannot differentiate between the two.

Now for the first time, the NTU-developed probe has made it possible to see the locations and levels of the two species, providing a potential new approach for visualising how a disease is developing or the body is reacting to a drug.

Professor Xing Bengang from NTU School of Physical and Mathematical Sciences who led the team said, "RNS and ROS are like the ‘twin rascals’ in our body, similar in their chemical properties and hard to differentiate when detected simultaneously. Being able to get information on their levels would give us clues about how certain diseases develop and how the body is responding to certain drugs. This could become a big advantage over imaging methods such as MRI and CT scans, which do not differentiate between the two reactive compounds RNS and ROS."

What is disease progression (HPD)? Hyperprogression of disease (HPD) is a model of NSCLC progression, a concept relative to "progression", defined as the rate of tumor growth after treatment is more than twice that before treatment.

-----------------------------------------------------------------------
Editor's Note: For any copyright disputes involving the content,
please email: Julia.Zhang@ubmsinoexpo.com to delete.